Sunday, 22 November 2026NewsWorldBusinessTech
Latest

Study Links Low-Dose Aspirin to Lower Metastatic Colorectal Cancer Odds

Regular low-dose aspirin use is associated with lower odds of presenting with synchronous distant metastatic colorectal cancer at diagnosis, according to a nationwide study published in the British Journal of Cancer.

Researchers evaluated data from 81,269 colorectal cancer patients identified across a 14-year period through the Colorectal Cancer Database Sweden (CRCBaSe). The study, authored by Mehrnoosh Shahrivar, Caroline E. Dietrich, Bengt Glimelius, and colleagues, found that patients actively taking prescribed low-dose aspirin had a 14 percent overall reduction in the adjusted odds of synchronous distant metastasis compared to non-users.

The inverse association appeared most pronounced among individuals diagnosed with right-sided colon tumors, where current aspirin use was linked to a 21 percent reduction in metastatic odds. A corresponding risk reduction was also identified among past aspirin users with right-sided lesions, persisting independently of exposure duration.

Content cover image
Photo: Nature

In fully adjusted models accounting for various clinical and demographic factors, current aspirin users exhibited an adjusted odds ratio of 0.86 for synchronous distant metastases. In duration-dependent analyses, past users had reduced odds of synchronous metastases only in right-sided colon cancer, while the reduction among current users persisted in right-sided colon cancer regardless of use duration and among rectal cancer patients with specific use patterns.

In contrast, this protective association did not consistently extend to left-sided colon malignancies.

Current users also demonstrated substantial baseline cardiovascular and metabolic comorbidity, with 69 percent carrying a diagnosed cardiovascular condition and 25 percent diagnosed with diabetes, compared to 22 percent and 8 percent among non-users.

Ethical approval for the investigation was acquired from the Regional Ethical Board in Stockholm, Sweden. Complete tracing for the study population was enabled through linkages using Sweden’s personal identification numbers connecting CRCBaSe with the National Patient Register, the Swedish Cancer Register, and the Longitudinal Integrated Database for Health Insurance and Labour Market Studies.

The Swedish Colorectal Cancer Registry has recorded clinical and pathological data on rectal cancer cases since 1995 and colon cancer cases since 2007, capturing tumor stage, anatomical subsite, and treatment.